AZD 6234
Alternative Names: AZD-6234Latest Information Update: 14 Nov 2024
Price :
$50 *
At a glance
- Originator AstraZeneca
- Class Obesity therapies; Peptides; Small molecules
- Mechanism of Action Amylin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
Most Recent Events
- 01 Oct 2024 Phase-II clinical trials in Obesity in Australia, Canada, United Kingdom (SC) (NCT06595238)
- 01 Oct 2024 Phase-II clinical trials in Obesity in USA (SC) (NCT06595238)
- 19 Sep 2024 AstraZeneca plans a phase II trial for Obesity in the US, Canada, Japan, United Kingdom and Australia (SC, Injection) (NCT06595238)